Amgen reports positive multiple myeloma study data for Kyprolis

Amgen has announced positive results from a phase III clinical trial that demonstrate the survival benefits its drug Kyprolis can deliver for multiple myeloma patients.

A final analysis of the ASPIRE trial showed that a regimen of Kyprolis, lenalidomide and dexamethasone was able to reduce patients' risk of death by 21 percent compared to lenalidomide and dexamethasone.

Patients treated with the Kyprolis-based regimen survived 7.9 months longer on average than those receiving lenalidomide and dexamethasone alone, highlighting Kyprolis is the first and only new drug to demonstrate improved overall survival compared to current standards of care.

This comes after another study called ENDEAVOR demonstrated the superior performance of Amgen's drug compared to another established therapy.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "This overall survival benefit from the ASPIRE trial further supports the importance of proteasome inhibition and duration of treatment with Kyprolis in the treatment of relapsed multiple myeloma."

Kyprolis is available for patients whose myeloma has relapsed or become resistant to other forms of treatment, and continues to be studied in a range of combinations and patient populations.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.